Clinicopathologic features of retinoblastoma after primary chemoreduction

被引:42
作者
Bechrakis, NE
Bornfeld, N
Schueler, A
Coupland, SE
Henze, G
Foerster, MH
机构
[1] Free Univ Berlin, Klinikum Benjamin Franklin, Dept Ophthalmol, D-12200 Berlin, Germany
[2] Free Univ Berlin, Klinikum Benjamin Franklin, Dept Pathol, D-12200 Berlin, Germany
[3] Univ Essen Gesamthsch, Dept Ophthalmol, Essen, Germany
[4] Humboldt Univ, Klinikum Rudolf Virchow, Dept Pediat Oncol Hematol, Berlin, Germany
关键词
D O I
10.1001/archopht.116.7.887
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: Primary chemotherapy is a new treatment approach in retinoblastoma, aiming to avoid radiogenic adverse effects, such as second tumor-associated mortality, as observed following external beam irradiation. Objective: To describe the clinical and histopathologic regression pattern after primary chemotherapy in retinoblastoma. Methods: Five patients with sporadic bilateral retinoblastoma underwent planned enucleation of their functionally blind eye after 2, 3 (in 2 patients), 4, and 6 courses of primary chemotherapy with carboplatin, etoposide, cyclophosphamide, and vincristine. The eyes were examined histopathologically, using light microscopy and immunohistochemical analysis with proliferation markers. Results: One patient had a type 1 (cottage cheese) regression and 4 patients had either a type 2 (fish flesh) or a type 3 (combined) regression pattern. Histopathologic examination revealed a complete tumor necrosis in 1 patient with type 1 regression after 3 courses of chemotherapy and in 1 patient with type 3 regression after 4 courses of chemotherapy. The remaining 3 patients with type 2 or type 3 regression had histologically still active proliferative tumor cells after 2, 3, and 6 courses of chemotherapy. Conclusion: This article correlates histopathologically the clinically described efficacy of primary chemotherapy in the treatment of retinoblastoma, underlining, however, the necessity of careful observation and the use of ancillary treatment whenever there is no complete tumor regression.
引用
收藏
页码:887 / 893
页数:7
相关论文
共 35 条
[1]   SPONTANEOUSLY REGRESSING RETINOBLASTOMAS, RETINOMA, OR RETINOBLASTOMA GROUP-0 [J].
AABY, AA ;
PRICE, RL ;
ZAKOV, ZN .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1983, 96 (03) :315-320
[2]  
BUYS RJ, 1983, ARCH OPHTHALMOL-CHIC, V101, P1206
[3]   2ND PRIMARY NEOPLASMS IN PATIENTS WITH RETINOBLASTOMA [J].
DRAPER, GJ ;
SANDERS, BM ;
KINGSTON, JE .
BRITISH JOURNAL OF CANCER, 1986, 53 (05) :661-671
[4]   MORTALITY FROM 2ND TUMORS AMONG LONG-TERM SURVIVORS OF RETINOBLASTOMA [J].
ENG, C ;
LI, FP ;
ABRAMSON, DH ;
ELLSWORTH, RM ;
WONG, FL ;
GOLDMAN, MB ;
SEDDON, J ;
TARBELL, N ;
BOICE, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (14) :1121-1128
[5]   Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy [J].
Gallie, BL ;
Budning, A ;
Deboer, G ;
Thiessen, JJ ;
Koren, G ;
Verjee, Z ;
Ling, V ;
Chan, HSL .
ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (11) :1321-1328
[6]  
GERDES J, 1984, J IMMUNOL, V133, P1710
[7]   Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy [J].
Greenwald, MJ ;
Strauss, LC .
OPHTHALMOLOGY, 1996, 103 (12) :1989-1997
[8]   PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IMMUNOLOCALIZATION IN PARAFFIN SECTIONS - AN INDEX OF CELL-PROLIFERATION WITH EVIDENCE OF DEREGULATED EXPRESSION IN SOME NEOPLASMS [J].
HALL, PA ;
LEVISON, DA ;
WOODS, AL ;
YU, CCW ;
KELLOCK, DB ;
WATKINS, JA ;
BARNES, DM ;
GILLETT, CE ;
CAMPLEJOHN, R ;
DOVER, R ;
WASEEM, NH ;
LANE, DP .
JOURNAL OF PATHOLOGY, 1990, 162 (04) :285-294
[9]  
Harbour JW, 1996, INVEST OPHTH VIS SCI, V37, P1892
[10]  
HAYS D, 1989, SURGERY